Diuretic therapy in heart failure;Tratamiento diurético en la insuficiencia cardiaca

Medicina Clinica

Volumn 142, Issue 4, 2014, Pages 163-170

  Trullàs, Joan Carles ^a   Morales Rull, José Luís ^b   Formiga, Francesc ^c  

^a UNIVERSITY OF GIRONA   (Spain)

^b HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^c BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

Congestive Heart Failure; Diuretics; Heart failure

Indexed keywords

DIURETIC AGENT;

DIURETIC THERAPY; DRUG USE; HEART FAILURE; HUMAN; REVIEW;

CONGESTIVE HEART FAILURE; DIURETICS; DIURÉTICOS; HEART FAILURE; INSUFICIENCIA CARDIACA; INSUFICIENCIA CARDIACA CONGESTIVA;

CARBONIC ANHYDRASE INHIBITORS; DIURESIS; DIURETICS; DIURETICS, POTASSIUM SPARING; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; NATRIURESIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM CHLORIDE SYMPORTER INHIBITORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 84893166773     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2013.04.027     Document Type: Review

References (48)

1. 1 Hunt, S.A., Abraham, W.T., Chin, M.H., Feldman, A.M., Francis, G.S., Ganiats, T.G., et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119 (2009), e391–e479.
2. 2 McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Böhm, M., Dickstein, K., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33 (2012), 1787–1847.
3. a ed, 2008, Editorial Elsevier Masson, 931–943 Capítulo 47.
4. 4 Adams, K.F. Jr., Fonarow, G.C., Emerman, C.L., LeJemtel, T.H., Costanzo, M.R., Abraham, W.T., et al., ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 (2005), 209–216.
5. 5 Gheorghiade, M., Filippatos, G., Reassessing treatment of acute heart failure syndromes: The ADHERE Registry. Eur Heart J Suppl 7:Suppl B (2005), B13–B19.
6. 6 Heywood, J.T., Fonarow, G.C., Costanzo, M.R., Mathur, V.S., Wigneswaran, J.R., Wynne, J., ADHERE Scientific Advisory Committe and Investigators. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: A report from the ADHERE database. J Card Fail 13 (2007), 422–430.
7. 7 Eshaghian, S., Horwich, T.B., Fonarow, G.C., Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97 (2006), 1759–1764.
8. 8 Felker, G.M., Lee, K.L., Bull, D.A., Redfield, M.M., Stevenson, L.W., Goldsmith, S.R., et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364 (2011), 797–805.
9. 9 Ernst, M.E., Moser, M., Use of diuretics in patients with hypertension. N Engl J Med 361 (2009), 2153–2164.
10. 10 Messerli, F.H., Bangalore, S., Half a century of hydrochlorothiazide: Facts, fads, fiction, and follies. Am J Med 124 (2011), 896–899.
11. 11 Consejo General de Colegios Oficiales de Farmacéuticos. BOT Plus web. Versión 5.0.0. Febrero 2011. Disponible en: https://botplusweb.portalfarma.com.
12. 12 Jentzer, J.C., DeWald, T.A., Hernandez, A.F., Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 56 (2010), 1527–1534.
13. 13 Sigurd, B., Olesen, K.H., Wennevold, A., The supra-additive natriuretic effect addition of bendroflumethiazide and bumetanide in congestive heart failure. Permutation trial tests in patients in long-term treatment with bumetanide. Am Heart J 89 (1975), 163–167.
14. 14 Dormans, T.P., Gerlag, P.G., Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. Eur Heart J 17 (1996), 1867–1874.
15. 15 Kiyingi, A., Field, M.J., Pawsey, C.C., Yiannikas, J., Lawrence, J.R., Arter, W.J., Metolazone in treatment of severe refractory congestive cardiac failure. Lancet 335 (1990), 29–31.
16. 16 Channer, K.S., McLean, K.A., Lawson-Matthew, P., Richardson, M., Combination diuretic treatment in severe heart failure: A randomised controlled trial. Br Heart J 71 (1994), 146–150.
17. 17 ClinicalTrials.gov. Safety and efficacy of the combination of loop with thiazide-type diuretics in patients with decompensated heart failure (CLOROTIC). Identifier: NCT01647932. [consultado 5 Mar 2013]. Disponible en: www.clinicaltrials.gov.
18. 18 Nappi, J.M., Sieg, A., Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. Vasc Health Risk Manag 7 (2011), 353–363.
19. 19 Struthers, A.D., Aldosterone: Cardiovascular assault. Am Heart J 144:5 Suppl (2002), S2–S7.
20. 20 Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 78 (1996), 902–907.
21. 21 Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003), 1309–1321.
22. 22 Zannad, F., McMurray, J.J., Krum, H., van Veldhuisen, D.J., Swedberg, K., Shi, H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364 (2011), 11–21.
23. 23 Bansal, S., Lindenfeld, J., Schrier, R.W., Sodium retention in heart failure and cirrhosis: Potential role of natriuretic doses of mineralocorticoid antagonist?. Circ Heart Fail 2 (2009), 370–376.
24. 24 Pérez-Ayuso, R.M., Arroyo, V., Planas, R., Gaya, J., Bory, F., Rimola, A., et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 84:5 Pt 1 (1983), 961–968.
25. 25 Van Vliet, A.A., Donker, A.J., Nauta, J.J., Verheugt, F.W., Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 71 (1993), 21A–28A.
26. 26 Hensen, J., Abraham, W.T., Dürr, J.A., Schrier, R.W., Aldosterone in congestive heart failure: Analysis of determinants and role in sodium retention. Am J Nephrol 11 (1991), 441–446.
27. 27 Brater, D.C., Diuretic therapy. N Engl J Med 339 (1998), 387–389.
28. 28 Khan, M.I., Treatment of refractory congestive heart failure and normokalemic hypochloremic alkalosis with acetazolamide and spironolactone. Can Med Assoc J 123 (1980), 883–887.
29. 29 Krämer, B.K., Schweda, F., Kammerl, M., Riegger, G.A., Diuretic therapy and diuretic resistance in cardiac failure. Nephrol Dial Transplant 14 (1999), 39–42.
30. 30 Neuberg, G.W., Miller, A.B., O'Connor, C.M., Belkin, R.N., Carson, P.E., Cropp, A.B., et al., PRAISE Investigators. Prospective Randomized Amlodipine Survival Evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 144 (2002), 31–38.
31. 31 Feenstra, J., Heerdink, E.R., Grobbee, D.E., Stricker, B.H., Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: The Rotterdam Study. Arch Intern Med 162 (2002), 265–270.
32. 32 Loon, N.R., Wilcox, C.S., Unwin, R.J., Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 36 (1989), 682–689.
33. 33 Kaissling, B., Stanton, B.A., Adaptation of distal tubule and collecting duct to increased sodium delivery. I. Ultrastructure. Am J Physiol 255:6 Pt 2 (1988), F1256–F1268.
34. 34 Kaissling, B., Bachmann, S., Kriz, W., Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment. Am J Physiol 248:3 Pt 2 (1985), F374–F381.
35. 35 Alexander, W.D., Branch, R.A., Levine, D.F., Hartog, M., The urinary sodium: Potassium ratio and response to diuretics in resistant oedema. Postgrad Med J 53 (1977), 117–121.
36. a ed, 2011, Enfoque Editorial S.C., Madrid, 38–40 Capítulo 11.
37. 37 Escobar, C., Sánchez-Zamorano, M.A., Manzano, L., Diuretic strategies in patients with acute heart failure. N Engl J Med, 364, 2011, 2067.
38. 38 Damman, K., O'Connor, C.M., Dangerous diuretics or death defying drugs?. Eur J Heart Fail 13 (2011), 1157–1158.
39. 39 Yilmaz, M.B., Gayat, E., Salem, R., Lassus, J., Nikolaou, M., Laribi, S., et al. Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis. Eur J Heart Fail 13 (2011), 1244–1252.
40. 40 Gheorghiade, M., Gattis, W.A., O'Connor, C.M., Adams, K.F. Jr., Elkayam, U., Barbagelata, A., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA 291 (2004), 1963–1971.
41. 41 Gheorghiade, M., Niazi, I., Ouyang, J., Czerwiec, F., Kambayashi, J., Zampino, M., et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind randomized trial. Circulation 107 (2003), 2690–2696.
42. 42 Konstam, M.A., Gheorghiade, M., Burnett, J.C. Jr., Grinfeld, L., Maggioni, A.P., Swedberg, K., et al. Effects of oral tolvaptan in patients hospitalized with worsening heart failure: The EVEREST Outcome Trial. JAMA 297 (2007), 1319–1331.
43. 43 Udelson, J.E., Smith, W.B., Hendrix, G.H., Painchaud, C.A., Ghazzi, M., Thomas, I., et al. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104 (2001), 2417–2423.
44. 44 Goldsmith, S.R., Gilbertson, D.T., Mackedanz, S., Swan, S.K., Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure. J Card Fail 17 (2011), 982–989.
45. 45 Costanzo, M.R., Guglin, M.E., Saltzberg, M.T., Jessup, M.L., Bart, B., Teerlink, J.R., et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49 (2007), 675–683.
46. 46 Bart, B., Goldsmith, S.R., Lee, K.L., Givertz, M.M., O'Connor, C.M., Bull, D., et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367 (2012), 2296–2304.
47. 47 Paterna, S., Fasullo, S., Parrinello, G., Cannizzaro, S., Basile, I., Vitrano, G., et al. Short-term effects of hypertonic saline solution in acute heart failure and long-term effects of a moderate sodium restriction in patients with compensated heart failure with New York Heart Association class III (Class C) (SMAC-HF Study). Am J Med Sci 342 (2011), 27–37.
48. 48 Giamouzis, G., Butler, J., Starling, R.C., Karayannis, G., Nastas, J., Parisis, C., et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: Results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail 16 (2010), 922–930.